Patents by Inventor Pablo Umaña

Pablo Umaña has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20230076791
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: May 25, 2022
    Publication date: March 9, 2023
    Inventors: Marina BACAC, Thomas HOFER, Ralf HOSSE, Christiane NEUMANN, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
  • Bispecific antibody molecules binding to CD3 and EGFRvIII
    Patent number: 11591397
    Abstract: The present invention generally relates to antibodies that bind to CD3, including multi specific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: September 14, 2021
    Date of Patent: February 28, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Anne Freimoser-Grundschober, Thomas Hofer, Ralf Hosse, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umaña, Inja Waldhauer, Wolfgang Richter, Alexander Knaupp, Halina Trochanowska
  • TREATMENT METHOD
    Publication number: 20230052521
    Abstract: The present invention relates to methods of treating a disease, and methods for reduction of the formation of anti-drug antibodies (ADAs) in response to the administration of a therapeutic agent. The invention further relates to methods of treating a disease, particularly a B-cell proliferative disorder, and methods for reduction of adverse effects in response to the administration of a therapeutic agent, particularly a T-cell activating therapeutic agent.
    Type: Application
    Filed: May 19, 2022
    Publication date: February 16, 2023
    Inventors: Marina BACAC, Stefan EVERS, Christian KLEIN, Pavel PISA, Eva ROSSMANN, Jose SARO, Pablo UMANA
  • BISPECIFIC ANTIGEN BINDING MOLECULES COMPRISING ANTI-4-1BB CLONE 20H4.9
    Publication number: 20230045262
    Abstract: The invention relates to new bispecific antigen binding molecules, comprising at least one antigen binding domain capable of specific binding to 4-1BB, at least one moiety capable of specific binding to a target cell antigen, and a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: August 15, 2022
    Publication date: February 9, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Claudia FERRARA KOLLER, Christina CLAUS, Christian KLEIN, Pablo UMAÑA, Wei XU
  • Antibodies binding To HLA-A2/WT1
    Publication number: 20220411534
    Abstract: The present invention generally relates to antibodies that bind to HLA-A2/WT1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: November 4, 2021
    Publication date: December 29, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg Benz, Christian Klein, Stefan Klostermann, Ekkehard Moessner, Johannes Sam, Pablo Umaña, Lydia Jasmin Hanisch, Alexander Bujotzek, Wei Xu
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20220403027
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: April 1, 2022
    Publication date: December 22, 2022
    Inventors: Oliver AST, Marina BACAC, Sabine IMHOF-JUNG, Christiane NEUMANN, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMANA
  • ANTIBODIES FOR CHELATED RADIONUCLIDES
    Publication number: 20220389116
    Abstract: The present application relates to antibodies which bind specifically to chelated radionuclides, including bispecific antibodies. It further relates to the use of such bispecific antibodies in applications such as radioimmunoimaging and radioimmunotherapy. It additionally relates to clearing agents and compositions useful in such methods. The chelated radionuclides may be a DOTAM-lead (Pb) chelate.
    Type: Application
    Filed: April 16, 2019
    Publication date: December 8, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christian KLEIN, Pablo UMANA, Alexander HAAS, Barbara WEISER, Florian LIPSMEIER, Guy GEORGES, Sebastian FENN, Joerg MOELLEKEN, Felix BORMANN, Daniela MATSCHEKO
  • Bispecific T cell activating antigen binding molecules
    Patent number: 11459404
    Abstract: The present invention generally relates to bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: October 4, 2022
    Assignee: Roche Glycart AG
    Inventors: Marina Bacac, Peter Bruenker, Christiane Neumann, Christian Klein, Ekkehard Moessner, Pablo Umana, Tina Weinzierl
  • Bispecific antigen binding molecule for a costimulatory TNF receptor
    Patent number: 11453722
    Abstract: The invention relates to novel bispecific antigen binding molecules comprising (a) at least one moiety capable of specific binding to OX40, and (b) at least one moiety capable of specific binding to tenascin C (TnC), and to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: September 27, 2022
    Assignee: Hoffmann La-Roche Inc.
    Inventors: Maria Amann, Sandra Grau-Richards, Christian Klein, Mudita Pincha, Pablo Umaña
  • Bispecific antigen binding molecules comprising anti-4-1BB clone 20H4.9
    Patent number: 11447558
    Abstract: The invention relates to new bispecific antigen binding molecules, comprising at least one antigen binding domain capable of specific binding to 4-1BB, at least one moiety capable of specific binding to a target cell antigen, and a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: September 20, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Claudia Ferrara Koller, Christina Claus, Christian Klein, Pablo Umaña, Wei Xu
  • ANTI-FAP ANTIBODIES AND METHODS OF USE
    Publication number: 20220281995
    Abstract: The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.
    Type: Application
    Filed: May 13, 2022
    Publication date: September 8, 2022
    Applicant: Roche Glycart AG
    Inventors: Marina BACAC, Anne FREIMOSER-GRUNDSCHOBER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Valeria G. NICOLINI, Pablo UMANA
  • PROTEASE-ACTIVATED T CELL BISPECIFIC MOLECULES
    Publication number: 20220275087
    Abstract: The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.
    Type: Application
    Filed: December 2, 2021
    Publication date: September 1, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Rebecca CROASDALE-WOOD, Christian KLEIN, Juergen Michael SCHANZER, Kay-Gunnar STUBENRAUCH, Pablo UMANA, Martina GEIGER, Eric SULLIVAN, Jigar PATEL
  • ANTIGEN BINDING MOLECULES COMPRISING A TRIMERIC TNF FAMILY LIGAND
    Publication number: 20220267395
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) a polypeptide comprising three ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by peptide linkers and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: November 18, 2021
    Publication date: August 25, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Pablo Umana
  • FUSION OF AN ANTIBODY BINDING CEA AND 4-1BBL
    Publication number: 20220267464
    Abstract: The invention relates to new humanized CEA antibodies and to CEA targeting 4-1BBL trimer-containing antigen binding molecules comprising these CEA antibodies as well as their use in the treatment of cancer.
    Type: Application
    Filed: December 17, 2021
    Publication date: August 25, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Claudia Ferrara Koller, Thomas Hofer, Christian Klein, Ekkehard Moessner, Christina Claus, Ralf Hosse, Bianca Scherer, Pablo Umana
  • ANTIBODIES WHICH BIND TO CANCER CELLS AND TARGET RADIONUCLIDES TO SAID CELLS
    Publication number: 20220267463
    Abstract: The present invention relates to antibodies which bind to antigens on target cells and which target radionuclides to said cells, and to methods of using the same.
    Type: Application
    Filed: July 10, 2020
    Publication date: August 25, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Pablo UMANA, Sabine IMHOF-JUNG, Alexander HAAS, Christian KLEIN, Sofia FROST, Felix BORMANN, Guy GEORGES, Sebastian FENN, Florian LIPSMEIER, Daniela MATSCHEKO, Joerg MOELLEKEN, Barbara WEISER
  • ANTIGEN BINDING MOLECULES COMPRISING A TNF FAMILY LIGAND TRIMER
    Publication number: 20220259327
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.
    Type: Application
    Filed: January 21, 2022
    Publication date: August 18, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Joerg Thomas Regula, Pablo Umana
  • BISPECIFIC ANTIBODIES SPECIFIC FOR PD1 AND TIM3
    Publication number: 20220259314
    Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to 5 TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: September 3, 2021
    Publication date: August 18, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: LAURA CODARRI-DEAK, GEORG FERTIG, JENS FISCHER, CHRISTIAN KLEIN, VIKTOR LEVITSKI, VALERIA LIFKE, MARIO PERRO, JOERG THOMAS REGULA, TILMAN SCHLOTHAUER, STEFAN SEEBER, PABLO UMANA, ILDIKO WUENSCHE, ADRIAN ZWICK
  • ANTIGEN BINDING MOLECULES COMPRISING A TNF FAMILY LIGAND TRIMER
    Publication number: 20220259326
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.
    Type: Application
    Filed: January 21, 2022
    Publication date: August 18, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Joerg Thomas Regula, Pablo Umana
  • Immunoconjugates
    Patent number: 11413331
    Abstract: The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: August 16, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Christian Klein, Laura Lauener, Valeria G. Nicolini, Stefan Seeber, Pablo Umana, Inja Waldhauer
  • NOVEL IMMUNOCONJUGATES
    Publication number: 20220242971
    Abstract: The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.
    Type: Application
    Filed: September 27, 2021
    Publication date: August 4, 2022
    Applicant: Roche Glycart AG
    Inventors: Oliver AST, Peter BRUENKER, Thomas U. HOFER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA